Skip to main content
Premium Trial:

Request an Annual Quote

Keith Elliston, Douglas Danne, John McAlister


After some time off following the split of Viaken Systems into two entities in June, Keith Elliston, founder and former CEO of Viaken, has resurfaced as CEO of Genstruct of Cambridge, Mass. Prior to founding Viaken in 1999, Elliston was the senior vice president of R&D and chief scientific officer at Gene Logic. He also founded the bioinformatics and genomics efforts of Bayer AG, where he was the worldwide head of bioinformatics and the section head for genomics, and spent 10 years in Merck’s computational molecular biology group. Elliston also holds a seat on Genstruct's board of directors.

Douglas Danne, formerly senior vice president and chief commercial officer of St. Louis-based Tripos, has left the company. CEO John McAlister said in a statement that the company is initiating a search for a replacement. Further details regarding Danne's departure were not provided.

Filed under

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.